Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression

BMC Cancer

Volumn 16, Issue 1, 2016, Pages

  Woodfield, Sarah E ^a   Zhang, Linna ^a   Scorsone, Kathleen A ^a   Liu, Yin ^b,c   Zage, Peter E ^a,d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c The University of Texas at Austin   (United States)

^d TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Binimetinib; ERK; MAPK; MEK; MEK162; Neuroblastoma; NF1

Indexed keywords

BINIMETINIB; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NF1 PROTEIN; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; NEUROFIBROMIN; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; MEK1 GENE; NEUROBLASTOMA CELL; NF1 GENE; OUTCOME ASSESSMENT; PRIMARY TUMOR; PROTEIN EXPRESSION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROBLASTOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BENZIMIDAZOLES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; NEUROFIBROMIN 1; PROTEIN KINASE INHIBITORS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84963762890     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-016-2199-z     Document Type: Article

References (47)

1. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, et al. Myeloablative Megatherapy with Autologous Stem-Cell Rescue Versus Oral Maintenance Chemotherapy as Consolidation Treatment in Patients with High-Risk Neuroblastoma: A Randomised Controlled Trial. Lancet Oncol. 2005;6:649-58.
2. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007-13.
3. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged Versus Non-Purged Peripheral Blood Stem-Cell Transplantation for High-Risk Neuroblastoma (COG A3973): A Randomised Phase 3 Trial. Lancet Oncol. 2013;14:999-1008.
4. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Op Cell Biol. 1997;9:180-6.
5. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37-40.
6. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci. 1995;92:7686-9.
7. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5:810-6.
8. Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6:2209-19.
9. Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, et al. Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models. Mol Cancer Ther. 2010;9:134-44.
10. Winski S, Anderson D, Bouhana K, Rhodes S, Impastato R, Woessner R, et al. MEK162 (ARRY-162), a novel MEK1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations. Eur J Cancer Suppl. 2010;8:56.
11. Bid HK, Kibler A, Phelps DA, Manap S, Xiao L, Lin J, et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res. 2013;19:6716-29.
12. Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry. 2009;48:2661-74.
13. Liang H, Liu T, Chen F, Liu Z, Liu S. A full-length 3D structure for MAPK/ERK kinase 2 (MEK2). Sci China Life Sci. 2011;54:336-41.
14. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 2004;11:1192-7.
15. Trujillo JI. MEK inhibitors: a patent review 2008-2010. Expert Opin Ther Pat. 2011;21:1045-69.
16. Pheneger J, Wallace E, Marlow A, Hurley B, Lyssikatos J, Bendele AM, Lee PA. Characterization of ARRY-438162, a potent MEK inhibitor in combination with methotrexate or ibuprofen in in vivo models of arthritis [abstract]. American College of Rheumatology; 2006 Annual Scientific Meeting.
17. Lee P, Wallace E, Marlow A, Yeh T, Marsh V, Anderson D, et al. Preclinical development of ARRY-162, a potent and selective MEK1/2 inhibitor [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010. Abstract number 2515.
18. Bendell JC, Papadopoulos K, Jones SF, Barrett E, Guthrie K, Kass CL, et al. Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors. Mol Cancer Ther. 2011;10(Supplement 1):B243.
19. Finn RS, Javie MM, Tan BR, Weekes CD, Bendell JC, Patnaik A, et al. A phase I study of MEK inhibitor MEK162 (ARRY-438162) in patients with biliary tract cancer [abstract]. J Clin Oncol. 2012;30(4_suppl):220.
20. Chi P, Qin LX, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, et al. A phase Ib/II study of MEK162 (binimetinib) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol. 2015;33(Suppl):10507.
21. Grisham RN, Gordon MS, Harb WA, Aghajanian C, McMeekin DS, McKinley K, et al. A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer [abstract]. J Clin Oncol. 2015;33(Suppl):5516.
22. Sosman JA, Kittaneh M, Lolkema MP, Postow M, Schwartz G, Franklin C, et al. A phase Ib/II study of LEE011 in combination with binimetinib (MEK162) in patients with advanced NRAS-mutant melanoma: early encouraging clinical activity [abstract]. J Clin Oncol. 2014;32(Suppl):9009.
23. Juric D, Soria JC, Sharma S, Banerji U, Azaro A, Desai J, et al. A phase Ib open-label, multicenter, dose-escalation and -expansion study of orally administered binimetinib (MEK162) plus BYL719 in adult patients with selected advanced solid tumors [abstract]. J Clin Oncol. 2014;32(Suppl):9051.
24. Shimokata T, Watanabe K, Shibata T, Inada-Inoue M, Shirao K, Hirashima Y, et al. Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors [abstract]. Eur J Cancer. 2013;49:3746.
25. van Herpen CML, Agarwala SS, Hauschild A, Dummer R, Berking C, Beck JT, et al. Overall survival and biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS-mutant melanoma. Ann Oncol. 2014;25:1-41.
26. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249-56.
27. Shukla N, Ameur N, Yilmaz I, Nafa K, Lau C-Y, Marchetti A, et al. Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma With Mutated Genes in Growth Signaling Pathways. Clin Cancer Res. 2011;18:748-57.
28. Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Gen. 2015;47:864-71.
29. Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell. 2010;142:218-29.
30. Biedler JL, Helson L, Spengler BA. Morphology and Growth, Tumorigenicity, and Cytogenetics of Human Neuroblastoma Cells in Continuous Culture. Cancer Res. 1973;33:2643-52.
31. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic Features of Human Neuroblastomas and Cell Lines. Cancer Res. 1981;41:4678-86.
32. Reynolds CP, Tomayko MM, Donner L, Helson L, Seeger RC, Triche TJ, et al. Biological Classification of Cell Lines Derived from Human Extra-Cranial Neural Tumors. Prog Clin Biol Res. 1988;271:291-306.
33. Schlesinger HR, Gerson JM, Moorhead PS, Maguire H, Hummeler K. Establishment and Characterization of Human Neuroblastoma Cell Line. Cancer Res. 1976;36:3094-100.
34. Sugimoto T, Tatsumi E, Kemshed JT, Helson L, Green AA, Minowada J. Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer Inst. 1984;73:51-7.
35. Helson L, Helson C. Human neuroblastoma cells and 13-cis-retinoic acid. J Neurooncol. 1985;3:39-41.
36. Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, et al. Human Neuroblastoma and Abnormalities of Chromosomes 1 and 17. Cancer Res. 1984;44:5444-9.
37. Shapiro D, Valentine M, Rowe S, Sinclair A, Sublett J, Roberts W, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization; diagnostic utility for neuroblastoma. Am J Pathol. 1993;142:1339-46.
38. Schwab M, Alitalo K, Klempnauer K, Varmus H, Bishop J, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature. 1983;305:245-8.
39. Zhang L, Scorsone K, Woodfield SE, Zage PE. Sensitivity of Neuroblastoma to the Novel Kinase Inhibitor Cabozantinib Is Mediated by ERK Inhibition. Cancer Chemother Pharmacol. 2015;76:977-87.
40. Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, et al. UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. Cancer. 2013;119:915-23.
41. Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, et al. GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. Cancer Res. 2014;74:2604-16.
42. The I, Murthy AE, Hannigan GE, Jacoby LB, Menon AG, Gusella JF, et al. Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Gen. 1993;3:62-6.
43. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature. 1992;356:713-5.
44. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63:851-9.
45. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63:843-9.
46. Urner-Bloch U, Urner M, Stieger P, Galliker N, Winterton N, Zubel A, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol. 2014;25:1437-41.
47. Bhagwat SS. MAP Kinase Inhibitors in Inflammation and Autoimmune Disorders. Ann Rep Med Chem. 2007;42:265-78.